Scheibler Lukas's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Feb 14, 2022
- Accession no.
- 0001127602-22-004908
- Filed
- Feb 14, 2022
- Trade date
- Feb 11, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $78.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scheibler LukasCIK 0001651281 | Officer (CHIEF INNOVATION OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 | Common Stock | SSaleDisposed | −1,666 | $46.80 | −$77,968.8 | 51,513 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.